fbpx
  • About us
  • Advertise
  • Contact
  • Nominate
  • Client’s Voice
  • Login
  • Register
📖 Magazine
The Global Economics
  • Home
  • Banking
  • Non Banking
  • Markets
  • Infrastructure
  • Lifestyle
  • FeatureNew
  • Awards
No Result
View All Result
  • Home
  • Banking
  • Non Banking
  • Markets
  • Infrastructure
  • Lifestyle
  • FeatureNew
  • Awards
No Result
View All Result
The Global Economics
No Result
View All Result
Home Infrastructure Healthcare

Cipla and Glenmark received approval for Inhalation Solution from US FDA

The Indian pharmaceutical market grew in April and May with 51.5% and 47.8% year-on-year, respectively

The Global Economics by The Global Economics
June 23, 2021
in Healthcare, Top Stories, Wealth & Asset Management
Reading Time: 2 mins read
0
Cipla and Glenmark received approval for Inhalation Solution from US FDA

Cipla and Glenmark received approval for Inhalation Solution from US FDA

746
SHARES
4.1k
VIEWS
FacebookTwitterRedditWhatsAppLinkedInShare Link

The key players in the drug manufacturing Cipla and Glenmark got the final approval for Arformoterol Tartrate Inhalation Solution from the United States Food and Drug Administration (US FDA). The solution provides relief from chronic bronchitis and emphysema. The Arformoterol Tartrate Inhalation Solution 15 mcg/2 ml stands as a basic version of Sunovion Pharmaceuticals Inc’s Brovana for both companies.

Patients with chronic obstructive pulmonary disease (COPD) require long-term administration of Brovana, a long-acting beta-2 adrenergic agonist (beta-2 agonist). The drug administration indication is twice a day (morning and evening). The US sales are nearly USD 438 million for the 12 months ending April 2021, per the IQVIA (IMS Health) data. Cipla has informed immediate shipping availability of the drug.

Glenmark said that the North American manufacturing facility based in Monroe, North Carolina, would contain the drug manufacturing wing. Additionally, this is the first nebulizer approval for the company. Presently, Glenmark comprises 172 products with a US market distribution license and 44 abbreviated new drug applications awaiting approval with the USFDA.

Being a leader in the pharma industry, Cipla is racing ahead with robust technological improvements to offer therapies for Covid. It has a comprehensive portfolio of drugs and diagnostic kits for the novel disease. The company marked extraordinary revenue due to strong sales in the Q4 profit, up 73% at Rs 412 crore, total income at Rs 4,606 crore. The drugmaker plans to tap the foreign markets for comprehensive coronavirus vaccine services.

Glenmark announced the consolidated revenue was at INR. 1,09,439 million, recording an increase of 2.8% over the previous corresponding period. The company hit a 23-month high in shares in April of Rs 587.50, up 3 percent, on the BSE in intra-day trade. The company also announced Glenmark Life Sciences’ IPO consisting of a fresh issue of shares worth INR 1,160 crore and a sale offer of nearly 7.31 million shares by parent Glenmark Pharmaceuticals.

The Indian pharmaceutical market (IPM) growth rate zoomed swiftly in April and May with 51.5% and 47.8% year-on-year, respectively. According to analyst reports, the demand for the Covid drugs led the sales. Additionally, the market saw a high need for anti-infectives, respiratory, and vitamins, and minerals that increased 142%, 87%, and 60% year on year, respectively.

Tags: ApprovalBronchitisCiplaEmphysemaGlenmarkInhalationSolutionUSFDA
The Global Economics

The Global Economics

The Global Economics Limited is a UK based financial publication and a bi-annual business magazine giving thoughful insights into the financial sectors on various industries across the world. Our highlight is the prestigious country specific Annual Global Economics awards program where the best performers in various financial sectors are identified worldwide and honoured.

Related Posts

Meta shares increase the most since 2013 and earns $40 billion in share buybacks
Finance

Meta shares increase the most since 2013 and earns $40 billion in share buybacks

by Riya Thomas
February 3, 2023
Bank of England plans for its 10th successive interest-rate hike, stiffens for shallow recession
Funds

Bank of England plans for its 10th successive interest-rate hike, stiffens for shallow recession

by Riya Thomas
February 2, 2023
A Western Oil Milestone: Exxon Sets Historic High with Record $56 Billion Profit
Ultility

A Western Oil Milestone: Exxon Sets Historic High with Record $56 Billion Profit

by Riya Thomas
February 1, 2023
Adani Group shares plunged, resulting in the erasure of $72 billion after three-day selloffs
Funds

72 Billion Wiped Out: Adani Group Shares Plunge After Three-Day Selloffs

by Riya Thomas
January 30, 2023
Baidu, the Chinese search giant all set to launch a ChatGPT-style bot in March 2023
Technology

Baidu, the Chinese search giant all set to launch a ChatGPT-style bot in March 2023

by Riya Thomas
January 30, 2023
Facebook Twitter Instagram Youtube LinkedIn Soundcloud
The Global Economics

The Global Economics Limited is a UK based financial publication and a quarterly business magazine giving thoughtful insights into the financial sectors on various industries across the world. Our highlight is the prestigious country specific Annual Global Economics awards program where the best performers in various financial sectors are identified worldwide and honoured.

DMCA.com Protection Status

  • Privacy
  • Legal
  • Terms of Use
  • Client’s Voice
  • Server Status

norton verified - the global economics

Latest Posts

Data centre for cloud computing

Oracle To Invest $1.5 Billion Data Centre In Riyadh, Saudi Arabia

February 6, 2023
Swappable Batteries of Electric Scooter

Can Swappable Batteries For EVs Work? Singapore’s Mo Batteries Is Hopeful

February 6, 2023
Meta shares increase the most since 2013 and earns $40 billion in share buybacks

Meta shares increase the most since 2013 and earns $40 billion in share buybacks

February 3, 2023
Download The Global Economics PWA to your mobile or Desktop
PWA App Download
Download The Global Economics Android App to your mobile or Desktop
Android App
Download The Global Economics IOS App to your mobile or Desktop
IOS App

All Rights Reserved © 2020 | 🇬🇧 The Global Economics, Business Finance Publication - www.theglobaleconomics.uk 🌏

No Result
View All Result
  • About us
  • Awards
  • Magazine
  • Client’s Voice
  • Exclusive Coverage
  • Nominate
  • Login
  • Sign Up

All Rights Reserved © 2020 | 🇬🇧 The Global Economics, Business Finance Publication - www.theglobaleconomics.uk 🌏

Welcome Back!

Sign In with Facebook
Sign In with Linked In
OR

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Sign Up with Facebook
Sign Up with Linked In
OR

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Receive the latest news

Subscribe To Our Weekly Newsletter

Get notified about new articles, delivered right into your email inbox.

-
00:00
00:00

Queue

Update Required Flash plugin
-
00:00
00:00
Go to mobile version